The multivalent ADAR1-recruiting RNA editing system (MARRS) is an RNA editing platform that efficiently recruits endogenous ADAR1 to achieve precise adenosine-to-inosine editing. MARRS enables up to 1...

Here, we applied exponential population analysis to direct RNA sequencing data from HEK293T cells and peripheral human blood to identify candidate motif patterns for pseudouridine (Ψ), inosine (I), and 5-methylcytosine (m⁵C).

A computational framework applied exponential population analysis to direct RNA sequencing data from HEK293T cells and human blood to identify candidate motif patterns for pseudouridine, inosine and

Chemical science · Xiao S, Jia P, Niu K, Li X, Li X, Chang Y, Zhang Z, Yuan H, Li J, Liu M.

Nonsense mutations account for approximately 20% of pathogenic variants in inherited retinal diseases (IRDs). With advances in gene therapy, nucleic acid-based nonsense suppression strategies, including suppressor tRNAs, RNA pseudouridylation, and adenosine-to-inosine RNA editing, have demonstrated therapeutic potential in preclinical studies. These next-generation approaches offer substantial opportunities for engineering and optimization, with the potential to enable precise and efficient restoration of full-length functional proteins. In this review, we propose that IRDs represent an attractive group of diseases for the clinical translation of these next-generation therapies owing to their high burden of nonsense mutations and the unique advantages of ocular gene therapy. We further outline key strategies to accelerate clinical translation, spanning therapeutic engineering, preclinical validation, and mutation-guided clinical trial design.

The Inosine Pranobex Market size is expected to reach US$ 258.9 Million by 2034 from US$ 215.19 Million in 2025. The global market is expected to grow at a CAGR of 2.08% from 2026 to 2034. The latest released Inosine Pranobex Market study has evaluated the future growth potential of the global market and provides information and useful stats on market structure and size.

Nonsense mutations account for approximately 20% of pathogenic variants in inherited retinal diseases (IRDs). With advances in gene therapy, nucleic acid-based nonsense suppression strategies, including suppressor tRNAs, RNA pseudouridylation, and adenosine-to-inosine RNA editing, have demonstrated therapeutic potential in preclinical studies. These next-generation approaches offer substantial opportunities for engineering and optimization, with the potential to enable precise and efficient restoration of full-length functional proteins. In this review, we propose that IRDs represent an attractive group of diseases for the clinical translation of these next-generation therapies owing to their high burden of nonsense mutations and the unique advantages of ocular gene therapy. We further outline key strategies to accelerate clinical translation, spanning therapeutic engineering, preclinical validation, and mutation-guided clinical trial design.

Wave Life Sciences has secured alignment with the U.S. Food and Drug Administration (FDA) for a single, two-year registrational trial of WVE-006, an RNA editing oligonucleotide designed to treat alpha

The Inosine Acedoben Dimepranol Drugs Market Industry is expected to grow from 0.51(USD Billion) in 2024 to 1.2 (USD Billion) by 2032. The Inosine Acedoben Dimepranol Drugs Market CAGR (growth rate) i...

Inosine pranobex shows antiviral promise through multiple mechanisms and could accelerate the clinical development pathway for COVID-19 treatment.

The Inosine Acedoben Dimepranol Drugs Market Industry is expected to grow from 0.51(USD Billion) in 2024 to 1.2 (USD Billion) by 2032. The Inosine Acedoben Dimepranol Drugs Market CAGR (growth rate) i...

We find that Dorado detected a higher number of m6A events and enabled simultaneous detection of other RNA modifications (5-methylcytosine, pseudouridine, and inosine).

CWC22-regulated alternative splicing modulates efferocytic recycling of inosine in macrophages, thereby controlling fat mass.

Abstract. A-to-I RNA editing enzymatically converts adenosine (A) to inosine (I) in RNA molecules. During sexual reproduction in several filamentous ascomy